STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] Organogenesis Holdings Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Organogenesis Holdings Inc. (ORGO) – Schedule 13D/A (Amendment 10) filed 06/24/2025

The filing updates beneficial ownership information for a long-standing reporting group comprised of company founders, related trusts and affiliated investment vehicles. No purchase or sale prices are disclosed in the excerpt; however, the cover page states that the amendment was triggered by an event on June 24 2025.

Key ownership positions disclosed

  • Alan A. Ades: 22,319,836 shares (17.6% of Class A common), of which 11.2 million are held with sole voting/dispositive power and 11.1 million with shared power.
  • Albert Erani: 17,920,498 shares (14.1%) – approximately 6.8 million sole and 11.1 million shared.
  • Glenn H. Nussdorf: 11,912,841 shares (9.4%) – 11.0 million sole, 0.9 million shared.
  • Dennis Erani: 10,043,701 shares (7.9%) – 1.3 million sole, 8.7 million shared.
  • Organo PFG LLC: 8,279,490 shares (6.5%) – all sole voting/dispositive.
  • Other entities & individuals: Organo Investors LLC (2.9 million / 2.2%), Alan Ades 2014 GRAT (3.1 million / 2.4%) and Starr Wisdom (20,000 / <0.1%).

Based on the amounts reported, the group collectively controls approximately 76.4 million Class A shares. Although total shares outstanding are not provided in the excerpt, each of the first four individuals continues to exceed the 5% reporting threshold, indicating significant insider alignment with shareholders. The amendment does not specify whether positions increased or decreased relative to the prior filing.

No financial performance metrics, transaction prices or strategic commentary accompany the ownership data, suggesting that the filing is largely administrative—updating share counts and voting arrangements among a pre-existing insider group.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Filing updates insider group holdings; no strategic shift or price data—neutral governance disclosure.

This tenth amendment to the Schedule 13D re-states the stakes of key founders and affiliated entities in Organogenesis Holdings. The largest holder, Alan A. Ades, retains 17.6% of the float, while three other insiders each remain above 5%. Combined, the group reports 76.4 million shares, reinforcing concentrated ownership but providing no indication of fresh accumulation or planned corporate action. Because neither changes in percentage ownership nor intentions (Item 4) appear in the excerpt, I view the disclosure as routine and not materially catalytic for the share price in the short term. Investors may take comfort in sustained insider alignment, yet the absence of new initiatives or purchases limits immediate market impact.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Alan A. Ades
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Albert Erani
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Glenn H. Nussdorf
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Dennis Erani
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Starr Wisdom
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Organo PFG LLC
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Organo Investors LLC
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Alan Ades 2014 GRAT
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Albert Erani Family Trust dated 12/29/2012
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Dennis Erani 2012 Issue Trust dated 12/20/12
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
GN 2016 Family Trust u/a/d August 12, 2016
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
RED Holdings, LLC
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025
Josette Ades
Signature:/s/ William R. Kolb, Attorney-in-fact
Name/Title:William R. Kolb, Attorney-in-fact
Date:06/26/2025

FAQ

How many Organogenesis (ORGO) shares does Alan A. Ades report owning in the 13D/A?

22,319,836 Class A common shares, representing 17.6% of the class.

What event date triggered this Schedule 13D/A filing for ORGO?

The event date disclosed is June 24, 2025.

Which entity holds 8.3 million ORGO shares according to the filing?

Organo PFG LLC holds 8,279,490 shares (6.5% of the class).

Does Albert Erani remain a 5%+ beneficial owner of Organogenesis?

Yes. He reports 17,920,498 shares, or 14.1% of outstanding Class A stock.

How many shares are attributed to the Alan Ades 2014 GRAT in this amendment?

The trust is shown with 3,075,865 shares, equal to 2.4% of the class.
Organogenesis Hldgs Inc

NASDAQ:ORGO

ORGO Rankings

ORGO Latest News

ORGO Latest SEC Filings

ORGO Stock Data

709.44M
67.16M
46.69%
55.12%
8.03%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CANTON